TDC
MRTX

Thompson Davis & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Thompson Davis & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$41K Sell
875
-375
-30% -$20.9K 0.09% 235
2018
Q2 		$62K Hold
1,250
– – 0.15% 157
2018
Q1 		$38K Sell
1,250
-250
-17% -$6.94K 0.1% 209
2017
Q4 		$27K Buy
1,500
+1,000
+200% +$15.5K 0.06% 276
2017
Q3 		$6K Buy
+500
New +$2.89K 0.01% 828

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Thompson Davis & Co's MRTX Position: Q3 2018 in Review

Thompson Davis & Co reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 30% in Q3 2018, selling an estimated $20.9K and leaving 875 shares worth $41K. The position accounts for 0.09% of the portfolio, ranked #235.

Thompson Davis & Co first reported a position in MRTX in Q3 2017 and has held it in 5 quarters since. The position peaked at $62K in Q2 2018. 125 funds tracked by Wall St. Rank hold MRTX as of Q3 2018.

  • Thompson Davis & Co held 875 shares of Mirati Therapeutics, Inc. Common Stock worth $41K as of Q3 2018.
  • Thompson Davis & Co sold 375 Mirati Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $20.9K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.09% of Thompson Davis & Co's portfolio in Q3 2018, its #235 holding.
  • Thompson Davis & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2017 and has held it in 5 quarters since.
  • Thompson Davis & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $62K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.